SIMCERE PHARMACEUTICAL GROUP (NY:SCR)
7.87
+0.32 (4.24%)
| SIMCERE PHARMACEUTICAL GROUP (NY:SCR) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $7.55 | 52 Week High | $9.98 | ||
| Open | $7.60 | 52 Week Low | $4.76 | ||
| Day High | $7.88 | P/E | N/A | ||
| Day Low | $7.43 | EPS | $0.00 | ||
| Volume | 71,853 | ||||
| More SCR Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| THC | 2 | KLIC | 2 |
| APP | 2 | LWAY | 2 |
| GIL | 2 | SKS | 2 |
| HEB | 2 | CEL | 1 |
| TLCV | 1 | GERN | 1 |
| HAST | 1 | IRE | 1 |
Entities who have mentioned SCR
- Piper Jaffray | View Related Stories »
- Goldman Sachs | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- UBS | View Related Stories »
- Lazard | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Stock Buyback | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- Trading Radar | View Related Stories »
View All Major News StreetInsider.com Major News for SCR
- Simcere Pharma (SCR) Posts Q3 EPS of 4c, Misses Views
- Simcere Pharma (SCR) Misses Street's Q1 Views
- Simcere Pharma (SCR) Reports Q4 EPS of $0.12; Won't Issue Outlook
View All ReportsStreetInsider.com Reports on SCR
- Simcere Pharma (SCR) Posts Q3 EPS of 4c, Misses Views
- Trading Radar for 11/16: Lowe's (LOW), Pacific Sunwear (PSUN), Assured Guaranty (AGO), Franklin Covey (FC) Report
- Simcere Pharma (SCR) Announces Agreement to Acquire Tianjin Tianda Pharma; To Manufacture Rosuvastatin
- Susquehanna Upgrades Simcere Pharmaceutical Group (SCR) to Positive; Raises FY10-12 Estimates
- Piper Jaffray Downgrades Simcere Pharmaceutical (SCR) to Neutral; Higher Sales & Marketing Costs
View All Press ReleasesCompany Press Releases on SCR
- Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results
- Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
- SCOR combines growth and profitability to generate a net income of EUR 278 million in the first nine months of 2009, with shareholders' equity increasing to EUR 3.8 billion (EUR 20.84 per share)
- Simcere Pharmaceutical Group to Announce 2009 Third Quarter Earnings on Monday, November 16, 2009
- Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
StreetInsider Reports on SCR by Category
View All BlogsBlogs on SCR
- AOB's Cash Generation Provides Backstop to Earnings Miss
- Simcere Acquires Statin Manufacturing License
- The Complete List of Chinese ADR Stocks
- China Biotech Week in Review: Is CRO Consolidation a New Theme?
- Simcere Gains Majority Control of Vaccine Subsidiary
Comments on SCR
No comments are currently available.
